WallStSmart

BioNexus Gene Lab Corp Common stock (BGLC)vsEcolab Inc (ECL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ecolab Inc generates 309695% more annual revenue ($16.45B vs $5.31M). ECL leads profitability with a 12.8% profit margin vs -54.7%. ECL earns a higher WallStSmart Score of 57/100 (C).

BGLC

Avoid

26

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 7.52

ECL

Buy

57

out of 100

Grade: C

Growth: 5.3Profit: 7.5Value: 4.3Quality: 5.0
Piotroski: 3/9Altman Z: 2.17

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BGLC3 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.5210/10

Safe zone — low bankruptcy risk

ECL2 strengths · Avg: 9.0/10
Market CapQuality
$72.12B9/10

Large-cap with strong market position

Return on EquityProfitability
21.1%9/10

Every $100 of equity generates 21 in profit

Areas to Watch

BGLC4 concerns · Avg: 2.5/10
Market CapQuality
$5.56M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-35.9%2/10

ROE of -35.9% — below average capital efficiency

Revenue GrowthGrowth
-98.9%2/10

Revenue declined 98.9%

ECL3 concerns · Avg: 3.7/10
PEG RatioValuation
2.314/10

Expensive relative to growth rate

P/E RatioValuation
34.7x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BGLC

The strongest argument for BGLC centers on Price/Book, Debt/Equity, Altman Z-Score.

Bull Case : ECL

The strongest argument for ECL centers on Market Cap, Return on Equity.

Bear Case : BGLC

The primary concerns for BGLC are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : ECL

The primary concerns for ECL are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BGLC profiles as a turnaround stock while ECL is a value play — different risk/reward profiles.

BGLC carries more volatility with a beta of 2.19 — expect wider price swings.

ECL is growing revenue faster at 10.0% — sustainability is the question.

ECL generates stronger free cash flow (97M), providing more financial flexibility.

Bottom Line

ECL scores higher overall (57/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BioNexus Gene Lab Corp Common stock

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.

Ecolab Inc

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Ecolab Inc., headquartered in St. Paul, Minnesota, is an American corporation that develops and offers services, technology and systems that specialize in water treatment, purification, cleaning and hygiene in a wide variety of applications. It helps organizations both private market as well as public treat their water, not only for drinking directly, but also for use in food, healthcare, hospitality related safety and industry.

Want to dig deeper into these stocks?